Alliance to support biopharma in developing personalised medicine
Quintiles has formed a strategic alliance with London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, to offer the bio pharmaceutical industry innovative pharmacogenetics solutions to advance personalised medicine. Financial terms were not disclosed.
Under the non-exclusive alliance, Quintiles and London Genetics will collaborate to help biopharma companies take advantage of pharmacogenetic solutions, including novel biomarker and assay development services. By providing biopharma companies strategic advice on the application of pharmacogenetics and innovative pharmacogenetics solutions, Quintiles and London Genetics can help customers access additional resources and speed the delivery of targeted treatments.
‘Biopharmaceutical companies are under relentless pressure to replenish their product pipelines and deliver safer, more effective medicines,’ said Thomas Wollman, senior vice president, Quintiles Global Central Laboratories. ‘Through our alliance with London Genetics, we have world-class expertise to help early adopters of personalised medicine use genomic technologies to improve drug discovery and development, and a networked infrastructure to sup-port those efforts virtually anywhere in the world.’